BioCentury | Jan 11, 2021
Deals

Atopic dermatitis readout drives Sanofi’s $1.1B takeout of Kymab

More than a decade after Kymab was first backed by the Wellcome Trust to derive drug candidates from an engineered mouse model, the company has accepted a $1.1 billion takeout offer from Sanofi that closely...
BioCentury | Jan 9, 2021
Translation in Brief

Fusing camelid antibodies to toxin derivatives to treat botulism; plus BioNTech applies platform to multiple sclerosis, a molecule that stops axon degeneration and more

Antibody-toxin fusions as botulism treatmentTwo groups reported in Science Translational Medicine taking advantage of atoxic botulinum neurotoxin (BoNT) derivatives to deliver single-domain antibodies into neurons to treat botulism. A Boston Children’s Hospital group found that intramuscular...
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as...
BioCentury | Dec 31, 2020
Distillery Therapeutics

ERR-α identified as target in diabetic and hypertensive kidney disease

DISEASE CATEGORY: Renal INDICATION: Renal damage Promoting expression of the nuclear receptor ERR-α could treat kidney disease associated with diabetes and hypertension. Levels of ERR-α mRNA  were lower in microdissected human kidney samples samples from patients...
BioCentury | Dec 22, 2020
Targets & Mechanisms

Tissue-targeting autoantibodies as a driver of long COVID

One implication of the recent Yale study linking autoantibody production to the development of long COVID is that treatment with therapies directed at B cells or antibody clearance might prove useful in...
BioCentury | Dec 12, 2020
Product Development

Dec. 11 Quick Takes: AZ to run combo trial with Sputnik; plus Phase III hits for Lilly, AbbVie and TG, data from Immutep, NVS, Mycovia, Sarepta and Greenwich

Russian and AZ COVID vaccines in combo trialAstraZeneca plc (LSE:AZN; NASDAQ:AZN) will begin by year-end a clinical trial of its AZD1222, developed with the University of Oxford, in combination with the adenovirus serotype 26 (Ad26)...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

Roche’s mAb depletes regulatory T cellsRoche (SIX:ROG; OTCQX:RHHBY) and University College London scientists reported in Nature Cancer that the anti-CD25 mAb RG6292, which is in a Phase I trial in advanced...
BioCentury | Nov 12, 2020
Product Development

Lining up allogeneic CAR Ts at ASH: Data Byte

Promising efficacy data from China’s Bioheng are among the allogeneic CAR T cell updates at ASH this year.  The past year has seen a growing number of clinical readouts for off-the-shelf allogeneic...
Items per page:
1 - 10 of 8298